UTSA Presidential Lecture featuring Leonard Pinchuk UC Retama Auditorium 2.02.021 UTSA Circle - San Antonio

29.5843443-98.6173559

Date/Time: 09/14/201711:00 am - 12:00 pm

Location:UC Retama Auditorium 2.02.021 UTSA CircleSan Antonio,

United States

Leonard Pinchuk Ph.D., D.Sc., (h.c.), NAE presents

Dr. Leonard Pinchuk, recipient of BioMed SAs 2017 Award for Innovation in Healthcare and Bioscience, is a serial inventor and entrepreneur with over 120 issued U.S. patents and 80 publications, and has co-founded 10 biomedical companies. His major accomplishments include the invention of the worlds first commercially successful and most widely used angioplasty balloon catheters, the helical wire stent, the modular stent-graft, a drug-eluting stent (TAXUS), two biostable implantable biomaterials (polycarbonate urethane and poly(styrene-block-isobutylene-block-styrene)), a novel glaucoma shunt (InnFocus MicroShunt) and the next generation intraocular lens material.He received a B.Sc. in Chemistry from McGill University (1976), a Ph.D. interdisciplinary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005). He was inducted into AIMBE in 2007 and the National Academy of Engineering in 2012 and is the recipient of the 2017 Society for Biomaterials Technology, Innovation and Development Award.Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters, vascular grafts, stents, stent-grafts) which went public on the NASDAQ in 1994, was acquired by Pfizer, Inc. in 1996, and was then sold to Boston Scientific Corporation in 1998. Dr. Pinchuk founded Innovia LLC in 2002 and continues to serve as President and CEO. Innovia has incubated eight companies working in the fields of intraocular lenses, glaucoma shunts, radiation oncology catheters, urinary catheters, gene therapy and futuristic biomaterials. One of the Innovia spin-offs, InnFocus, Inc., developed a novel medical device to treat glaucoma and was acquired by Santen Pharmaceuticals in August 2016. Dr. Pinchuk will continue to serve as InnFocus CSO for the next three years. Dr. Pinchuk also enjoys an appointment as Research Professor of Biomedical Engineering at the University of Miami (Miami, FL).

Follow this link:
UTSA Presidential Lecture featuring Leonard Pinchuk - UTSA Today

Comments are closed.